Immunomodulators Global Business Analysis Report 2024-2030: Growing Focus on Combination Therapies Enhances Market Opportunities, Increased Focus on Developing Targeted Therapies
November 07, 2024 10:43 ET
|
Research and Markets
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Immunomodulators - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Immunomodulators...
GEn1E Lifesciences Publishes Breakthrough Research Unveiling Novel Mechanism of Action of Dual Signal Modulators for Anti-inflammatory and Endothelial-Stabilizing Therapies
October 14, 2024 06:02 ET
|
GEn1E Lifesciences Inc.
GEn1E Lifesciences today announced the publication of a landmark study in the prestigious Journal of Pharmacology and Experimental Therapeutics (JPET)
Global Immunomodulator Market Projected to Nearly Double, Reaching $477.55 Billion by 2034 - Evolution of Immunomodulatory Treatments for Cancer Creating Lucrative Opportunities for Oncology Applications
June 27, 2024 09:43 ET
|
Research and Markets
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Global Immunomodulator Market" report has been added to ResearchAndMarkets.com's offering.In a significant development for the healthcare industry,...
Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly
June 07, 2024 20:18 ET
|
Qu Biologics, Inc.
Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial...
Herbal TB Immunotherapy to be Presented at Hong Kong Conference
July 07, 2011 10:33 ET
|
Immune Network Ltd
VANCOUVER, British Columbia, July 7, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF) advises that clinical results from its new tableted form of Immunoxel (Dzherelo) product...
Immunitor Publishes Interim Data From Phase IIb imm01 TB Trial
December 30, 2010 04:41 ET
|
Immune Network Ltd
VANCOUVER, British Columbia, Dec. 30, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), advises that Immunitor has published data from the first half of the 120-patient imm01 clinical...
Immunitor Phase 2b imm01 Trial Enrollment Scheduled to Complete Next Week
November 01, 2010 09:42 ET
|
Immune Network Ltd
VANCOUVER, British Columbia, Nov. 1, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), a company in the business of discovery and development of immune-based therapies, today announced...